Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep525 | Thyroid | ECE2024

The epidemiological, clinical, and pathological characteristics of differentiated thyroid cancer in children and adolescents

Charfi Hana , Jardak Issam , Hamza Fatma , Maaloul Mohamed , Amouri Wissam , Charfeddine S , Guermazi Fadhel , Chtourou Khalil , Abid Mohamed , Rekik Majdoub Nabila

Introduction: Differentiated thyroid cancer (DTC) in children is rare, accounting for 1.5 to 3% of all pediatric cancers. Its clinical presentation differs from that in adults. The aim of our study is to investigate the epidemiological, clinical, and anatomopathological characteristics of DTC in children and adolescents.Patients and Methods: A descriptive retrospective study was conducted at the Nuclear Medicine Department of Habib Bourguiba University H...

ea0077p70 | Metabolism, Obesity and Diabetes | SFEBES2021

Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates

Allum Matthew , Buckley Adam , Lessan Nader , Mohammed Nagi , Suliman Mohamed , Suliman Sara , Elsheikh Mohgah

Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...

ea0077p85 | Neuroendocrinology and Pituitary | SFEBES2021

Clinical presentation of 209 surgically operated non-functioning pituitary macroadenomas

Edwards Mared , Hayhurst Caroline , Mohamed Amr , Davies J Steve , Rees D Aled , Lansdown Andrew

Background: The clinical presentation of non-functioning pituitary adenomas (NFAs) can range from an incidental finding on imaging to pituitary hormone deficiencies and visual compromise.Objective: To assess the clinical presentation of patients who had undergone surgical resection of histologically proven NFAs.Methods: Patients presenting to the University Hospital of Wales, Cardiff, with non-functioning pituitary adenomas (histol...

ea0078p57 | Pituitary and Growth | BSPED2021

Rapid-onset obesity, hypothalamic and autonomic dysregulation with neuroendocrine tumours: Can this be ROHHADNET?

Nadar Ruchi , Sakremath Rajesh , Kirk Jeremy , Randell Tabitha , Jenkinson Helen , Woodman Helen , Saraff Vrinda , Mohamed Zainaba

Introduction: ROHHADNET is a rare syndrome characterized by rapid onset obesity, hypoventilation, hypothalamic dysfunction, autonomic dysregulation and neuroendocrine tumours. Although obesity is the first recognisable feature, there is variable onset of other features, resulting in delayed or missed diagnosis, potentially leading to fatal consequences. We describe two cases with features of ROHHADNET, who had high heterogeneity in clinical spectrum. Cas...

ea0053p07 | (1) | OU2018

The use of ketogenic diet in a patient with post-prandial hyperinsulinemic hypoglycaemia after m Roux-en-Y Gastric Bypass surgery: a case study

Abbott Sally , Dindol Naomi , Singhal Rishi , Helmy Ahmed , Ahmed Mohamed , Bellary Sri , Tahrani Abd

Background: Hyperinsulinemic hypoglycaemia (HH) after Roux-en-Y gastric bypass (RYGB) is rare. Patients typically present with post-prandial hypoglycaemia >1 year after surgery and once weight loss has plateaued. Despite multiple treatment options, the management of these patients remains challenging.Clinical case: A 31-year-old female was referred for bariatric surgery with a BMI of 41.4 kg/m2. In the year preceding the r...

ea0051p050 | Pituitary and growth | BSPED2017

Siblings with 3-M Syndrome show good response to Growth Hormone (GH) therapy over a 4 year follow-up growth data

Mohamed Zainaba , Sachdev Pooja , Benson Joanna , Hastings Richard , Randell Tabitha , Denvir Louise

Introduction: 3M syndrome is a rare autosomal recessive condition that causes short stature, unusual facial features and skeletal abnormalities with normal intelligence. Mutations in CUL7, OBSL1 and CCDC8 genes have been identified as pathogenic. GH treatment outcomes for 3M syndrome appear controversial. Use of human recombinant GH for the treatment of short stature has been trialled in previous studies with some suggesting dysregulation in GH/IGF1 axis while others report no...

ea0081ep21 | Adrenal and Cardiovascular Endocrinology | ECE2022

Metabolic and cardiovascular consequences of hormone replacement by hydrocortisone in adrenal insufficiency

Charrada Ines , Wafa Alaya , Fadia Boubaker , Lassoued Najoua , Baha Zantour , Olfa Berrich , Habib Sfar Mohamed

Introduction: During adrenal insufficiency (AI), glucocorticoid treatment is supposed to be neutral on the metabolic parameters of patients. However, recent data from the literature report that this corticosteroid replacement therapy increases the metabolic risk. The aim of our work was to determine the metabolic and cardiovascular impact of hydrocortisone (HC) replacement therapy during peripheral AI.Patients and methods: This was a descriptive and anal...

ea0081ep27 | Adrenal and Cardiovascular Endocrinology | ECE2022

Impact on quality of life and sleep of hydrocortisone hormone replacement in adrenal insufficiency.

Charrada Ines , Wafa Alaya , Fadia Boubaker , Mrabet Houcem , Baha Zantour , Olfa Berrich , Habib Sfar Mohamed

Introduction: Hydrocortisone (HC) is the most widely used replacement molecule in the treatment of adrenal insufficiency (AI). This substitution treatment is far from ideal especially as it is impossible to reproduce the nycthemeral cycle of cortisol with its current galenic form which has a short half-life. The aim of our work was to determine the impact of HC treatment of peripheral AI on the long-term quality of life and sleep.Patients and methods: Th...

ea0081ep72 | Adrenal and Cardiovascular Endocrinology | ECE2022

Bone impact of hydrocortisone hormone replacement in adrenal insufficiency.

Charrada Ines , Wafa Alaya , Lassoued Najoua , Fadia Boubaker , Baha Zantour , Olfa Berrich , Habib Sfar Mohamed

Introduction: The treatment of adrenal insufficiency (AI) is based on long-term glucocorticoid substitution. Hydrocortisone (HC) is the most commonly used substitution molecule. The aim of our work was to determine the long-term bone impact of patients with peripheral AI.Patients and methods: This is a descriptive and analytical study involving 77 patients with peripheral IS (66 women and 11 men), all treated with HC. For each patient, we determined the ...

ea0081ep110 | Adrenal and Cardiovascular Endocrinology | ECE2022

Tertiary adrenal insufficiency revealing Gayet-Wernicke encephalopathy

Rifai Kaoutar , Guissi Loubna , Kamel Farah , Iraqi Hind , Gharbi Mohamed Elhassan

Introduction: Gayet-Wernicke encephalopathy (WE) is a rare neurological disorder, caused by thiamine (vitamin B1) deficiency. We report a case of tertiary adrenal insufficiency revealing Gayet-Wernicke encephalopathy.Case presentation: A 45-year-old women was admitted with abdominal pain, vomiting and weakness. Her medical history was significant for a long-term self-medication with corticosteroids and chronic vomiting. Clinical examination revealed a cu...